Preliminary results of treatment of intermediate-risk patients according to the AML-MRD-2018 protocol

Cover Page

Cite item

Full Text

Abstract

In the past decades, significant advancements have been made in the treatment of children with acute myeloid leukemia (AML) with the introduction of more effective treatment regimens, extended indications for hematopoietic stem cell transplantation as well as better supportive therapy and prophylaxis of infectious complications. Nevertheless, an improvement in treatment outcomes is still an important goal. One of the key ways to enhance treatment effectiveness is risk stratification of AML patients based on molecular and genetic characteristics of the disease. A multicenter treatment protocol (the AML-MRD-2018 protocol) was developed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. Our study includes 525 patients from 54 Russian hospitals who underwent treatment from November 2018 to December 2023. A total of 205 patients with a median age of 8.9 years (1 month – 17.6 years) were re-stratified to the intermediate-risk group. The 3-year overall and event-free survival for this group was 77% and 47%, respectively. The patients with biallelic CEBPA (dCEBPA) mutations had the most favorable prognosis. In the intermediate-risk group, early death before remission occurred in 6% of the patients; 8% of the patients died in first remission. Death of progressive disease occurred in 32% of all the deceased patients. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation.

About the authors

M. S. Vasilyeva

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: vmarie97@yandex.ru
ORCID iD: 0000-0002-9335-5286

Maria S. Vasilyeva - a hematologist at the Hematology/Oncology Isolation Unit.

1 Samory Mashela St., 117997, Moscow

Russian Federation

I. I. Kalinina

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-0813-5626

Moscow

Russian Federation

D. A. Venyov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-0183-1530

Moscow

Russian Federation

S. A. Lebedeva

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-1719-1726

Moscow

Russian Federation

V. A. Bankole

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-9533-6583

Moscow

Russian Federation

Z. А. Abashidze

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-6314-2132

Moscow

Russian Federation

O. V. Aleinikova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0003-0143-1921

Moscow

Russian Federation

Yu. V. Olshanskaya

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-2352-7716

Moscow

Russian Federation

E. A. Zerkalenkova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-9634-5828

Moscow

Russian Federation

M. V. Gaskova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-3277-9018

Moscow

Russian Federation

A. B. Itov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0003-0098-919X

Moscow

Russian Federation

A. M. Popov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-0889-6986

Moscow

Russian Federation

E. V. Mikhailova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-3450-0498

Moscow

Russian Federation

S. A. Kashpor

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-5220-7412

Moscow

Russian Federation

S. A. Plyasunova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-4503-0735

Moscow

Russian Federation

M. E. Dubrovina

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-8228-4876

Moscow

Russian Federation

T. V. Konyukhova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-6271-7435

Moscow

Russian Federation

K. A. Voronin

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-7578-9657

Moscow

Russian Federation

L. A. Khachatryan

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-7265-0414

Moscow

Russian Federation

D. D. Baydildina

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-7130-8596

Moscow

Russian Federation

G. A. Tsaur

Regional Children's Clinical Hospital

ORCID iD: 0000-0002-9881-6221

Yekaterinburg

Russian Federation

L. G. Fechina

Regional Children's Clinical Hospital

ORCID iD: 0000-0002-1885-3912

Yekaterinburg

Russian Federation

A. V. Popa

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation; The N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0001-5318-8033

Moscow

Russian Federation

A. A. Maschan

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-0016-6698

Moscow

Russian Federation

G. A. Novichkova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

ORCID iD: 0000-0002-2322-5734

Moscow

Russian Federation

References

  1. Reinhardt D., Antoniou E., Waack K. Pediatric Acute Myeloid Leukemia – Past, Present, and Future. J Clin Med 2022; 11 (3): 504.
  2. Elgarten C.W., Aplenc R. Pediatric acute myeloid leukemia: Updates on biology, risk stratification, and therapy. Curr Opin Pediatr 2020; 32 (1): 57–66.
  3. Shallis R.M., Wang R., Davidoff A., Ma X., Zeidan A.M. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev 2019; 36: 70–87.
  4. Kalinina I.I., Mas- chan A.A., Olshanskaya Yu.V., et al. Diagnosis and treatment of acute myeloid leukemia in children: a study guide. М.: D. Rogachev NMRCPHOI of Ministry of Healthcare of the Russian Federation; 2021. 104 p. (In Russ.).
  5. Czogała M., Balwierz W., Pawińska-Wąsikowska K., Książek T., Bukowska-Strakova K., Czogała W., et al. Advances in the first line treatment of pediatric acute myeloid leukemia in the polish pediatric leukemia and lymphoma study group from 1983 to 2019. Cancers (Basel) 2021; 13 (18): 4536.
  6. Bonaventure A., Harewood R., Stiller C.A., Gatta G., Clavel J., Stefan D.C., et al. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol 2017: 4 (5): e202–17.
  7. Burnett A.K., Hills R.K., Russell N. Twenty five years of UK trials in acute myeloid leukaemia: what have we learned? Br J Haematol 2020; 188 (1): 86–100.
  8. Rasche M., Zimmermann M., Steidel E., Alonzo T., Aplenc R., Bourquin J.-P., et al. Survival following relapse in children with acute myeloid leukemia: A report from AMLBFM and COG. Cancers (Basel) 2021; 13 (10): 2336.
  9. Egan G., Chopra Y., Mourad S., Chiang K.-Y., Hitzler J. Treatment of acute myeloid leukemia in children: A practical perspective. Pediatr Blood Cancer 2021; 68 (7): e28979.
  10. Kalinina I.I., Venyov D.A., Olshanskaya Yu.V., Sadovskaya M.N., Goronkova O.V., Salimova T.Yu., et al. The outcomes of children with acute myeloid leukemia treated in accordance with the AML–MM-2006 protocol. Pediatric Hematology/ Oncology and Immunopathology 2022; 21 (1): 20–35. (In Russ.). doi: 10.24287/1726-1708-2022-211-20-35
  11. Khoury J.D., Solary E., Abla O., Akkari Y., Alaggio R., Apperley J.F., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36 (7): 1703–19.
  12. Vujkovic M., Attiyeh E.F., Ries R.E., Goodman E.K., Ding Y., Kavcic M., et al. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: A Children’s Oncology Group report. Blood 2017; 129 (23): 3051–8.
  13. Arber D.A., Orazi A., Hasserjian R.P., Borowitz M.J., Calvo K.R., Kva- snicka H.-M., et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140 (11): 1200–28.
  14. Rubnib J.E., Razzouk B.I., Len- sing S., Pounds S., Pui C.-H., Ribeiro R.C. Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 2007; 109 (1): 157–63.
  15. Kelly M.J., Horan J.T., Alonzo T.A., Eapen M., Gerbing R.B., He W., et al. Comparable survival for pediatric acute myeloid leukemia with poorrisk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation. Pediatr Blood Cancer 2014; 61 (2): 269–75.
  16. Popov A.M., Verzhbitskaya T.Yu., Movchan L.V., Demina I.A., Mikhailova E.V., Semchenkova A.A., et al. Flow cytometry in acute leukemia diagnostics. Guidelines of Russian-Belarusian multicenter group for pediatric leukemia studies. Pediatric Hematology/Oncology and Immunopathology 2023; 22 (1): 165–77. (In Russ.). doi: 10.24287/1726-1708-202322-1-165-177
  17. Buldini B., Maurer-Granofszky M., Varotto E., Dworzak M.N. Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies. Front Pediatr 2019; 7: 412.
  18. Mikhailova E.V., Dages- tani A.N., Kashpor S.A., Plyasu- nova S.A., Konyukhova T.V., Dubrovina M.E., et al. Flow cytometric and cytomorphological definition of remission achievement in children with acute myeloid leukemia. Pediatric Hematology/Oncology and Immunopathology 2024; 23 (1): 73–85. (In Russ.). doi: 10.24287/1726-1708-2024-231-73-85
  19. ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024). Cytogenet Genome Res 2024; 164 (Suppl 1): 1–224.
  20. Gabert J., Beillard E., van der Velden V.H.J., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of “real time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program. Leukemia 2003; 17 (12): 2318–57.
  21. Sendker S., Awada A., Domagalla S.,Sendker M., Orhan E., Hoff- meister L.M., et al. RUNX1 mutation has no prognostic significance in paediatric AML: a retrospective study of the AML-BFM study group. Leukemia 2023; 37 (7): 1435–43.
  22. Dö Hner K., Paschka P. Intermediate-risk acute myeloid leukemia therapy: current and future. Hematology Am Soc Hematol Educ Program 2014; 2014 (1): 34–43.
  23. Klein K., Kaspers G., Harrison C.J., Berna Beverloo H., Reedijk A., Bongers M., et al. Clinical impact of additional cytogenetic aberrations, cKIT and RAS mutations, and treatment elements in pediatric t(8;21)AML: Results from an international retrospective study by the International Berlin-Frankfurt-Münster Study Group. J Clin Oncol 2015; 33 (36): 4247–58.
  24. Qiu K.-Y., Liao X.-Y., Li Y., Huang K., Xu H.-G., Fang J.-P., Zhou D.-H. Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16). BMC Cancer 2023; 23 (1): 476.
  25. Slinin A.S., Byda- nov O.I., Karachunskiy A.I. Analysis of survival and possibility of certain events in patients with acute leucosis. Pediatric Hematology/Oncology and Immunopathology 2016; 15 (3): 34–9. (In Russ.). doi: 10.24287/1726-17082016-15-3-34-39
  26. de Morais R.V., de Souza M.V.,de Souza Silva K.A., Pablo S., Cunha Lorenzoni M., Fernandes Lorea C., et al. Epidemiological evaluation and survival of children with acute myeloid leukemia. J Pediatr (Rio J) 2021; 97 (2): 204–10.
  27. Tseng S., Lee M.E., Lin P.C. A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment. Pharmaceuticals (Basel) 2023; 16 (11): 1614.
  28. Ho P.A., Alonzo T.A., Gerbing R.B., Pollard J., Stirewalt D.L., Hurwitz C., et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): A report from the Children’s Oncology Group. Blood 2009; 113 (26): 6558–66.
  29. Loken M.R., Alonzo T.A., Pardo L.,Gerbing R.B., Raimondi S.C., Hirsch B.A., et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: A report from Children’s Oncology Group. Blood 2012; 120 (8): 1581–8.
  30. Semchenkova A.A., Illarionova O.I., Demina I.A., Mikhailova E.V., Zerkalenkova E.A., Zakharova E.S., et al. Guidelines for the use of flow cell sorting in diagnosis and monitoring of acute leukemia. Pediatric Hematology/Oncology and Immunopathology 2023; 22 (4): 186–205. (In Russ.). doi: 10.24287/1726-17082023-22-4-186-205
  31. Steinbach D., Bader P., Willasch A., Bartholomae S., Debatin K.-M., Zimmermann M., et al. Prospective validation of a new method of monitoring minimal residual disease in childhood acute myelogenous leukemia. Clin Cancer Res 2015; 21 (6): 1353–9.
  32. Christakopoulos G.E., Walker K.N., Smith J., Takemoto C.M., Zheng Y., Pui C.-H., et al. Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods. Cancer 2023; 129 (12): 1873–84.
  33. Pollard J.A., Guest E., Alonzo T.A., Gerbing R.B., Loken M.R., Eidenschink Brodersen L., et al. Gemtuzumab Ozogamicin Improves EventFree Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children’s Oncology Group Trial AAML0531. J Clin Oncol 2021; 39 (28): 3149–60.
  34. Lambert J., Pautas C., Terré C., Raffoux E., Turlure P., Caillot D., et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 2019; 104 (1): 113–9.
  35. Fenwarth L., Fournier E., Cheok M., Boyer T., Gonzales F., Castaigne S., et al. Biomarkers of gemtuzumab ozogamicin response for acute myeloid leukemia treatment. Int J Mol Sci 2020; 21 (16): 5626.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Vasilyeva M.S., Kalinina I.I., Venyov D.A., Lebedeva S.A., Bankole V.A., Abashidze Z.А., Aleinikova O.V., Olshanskaya Y.V., Zerkalenkova E.A., Gaskova M.V., Itov A.B., Popov A.M., Mikhailova E.V., Kashpor S.A., Plyasunova S.A., Dubrovina M.E., Konyukhova T.V., Voronin K.A., Khachatryan L.A., Baydildina D.D., Tsaur G.A., Fechina L.G., Popa A.V., Maschan A.A., Novichkova G.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.